nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Psychotic Disorders"

 

Positive Results for a Non-D2 Antipsychotic
May 3, 2020   

The mainstay mechanism of action for available conventional and atypical antipsychotics typically involves antagonism or partial agonism of dopamine D2 receptors. However, currently available D2-binding antipsychotics often lack efficacy, especially in terms of negative and cognitive symptoms of schizophrenia, and may increase risk of potentially serious adverse events including motor symptoms and metabolic issues...
 Continue reading (Members only)
Transcranial Direct Current Stimulation (tDCS) as a Potential Treatment for Negative Symptoms of Schizophrenia
March 8, 2020   

In a recent double-blind randomized controlled study, the effects of transcranial direct current stimulation (tDCS) versus sham were examined as add-on treatment for negative symptoms...
 Continue reading (Members only)
FDA Warns of Serious Complications Following Clozapine-Induced Constipation
February 16, 2020   

The Food and Drug Administration strengthened an existing warning that constipation caused by the schizophrenia medicine clozapine can progress to...
 Continue reading (Members only)
Nationwide Cohort Study Shows Decreased Mortality With Long-term Antipsychotic Use
January 27, 2020   

Despite known adverse effects on cardiometabolic function, short-term antipsychotic use is also associated with lower mortality risk among persons with schizophrenia, and its effect of morbidity and mortality following long-term use is unclear. A nationwide observational study assessed the...
 Continue reading (Members only)
FDA Approves Lumateperone for Schizophrenia in Adults
January 14, 2020   

Schizophrenia is a lifelong illness affecting approximately 2.4 million Americans and is characterized by psychotic, negative, cognitive, and affective symptoms. Although there are numerous antipsychotic agents available to treat schizophrenia, optimized treatment for the individual patient varies and...
 Continue reading
2019 NEI Congress Highlights: What to Do When D2 Isn't Enough
November 9, 2019   

In a presentation at the 2019 NEI Congress, Dr. Andrew J. Cutler provided the most current information on pharmacological treatment options beyond targeting the dopamine 2 receptor.
 Continue reading
Clozapine vs. Other Atypical Antipsychotics: Meta-analysis
October 17, 2019   

Clozapine is the antipsychotic of choice for treatment-resistant schizophrenia (failure to respond after 2 adequate trials of antipsychotics). However, there have been conflicting results from randomized controlled trials (RCTs) comparing the efficacy of...
 Continue reading (Members only)
Meta-analysis: Comparative Efficacy and Tolerability of Antipsychotics
August 5, 2019   

A recent network meta-analysis, the largest to date, examined 32 different first-generation and second generation antipsychotics or placebo. Based on 402 studies including 53,463 participants on both placebo-controlled and...
 Continue reading (Members only)
Daily Use of High-Potency Cannabis Increases Risk of Psychosis Onset
April 8, 2019   

Cannabis is known to be associated with the risk of subsequent psychotic disorders, however whether it influences the incidence of the disorder is not clear. In a recent multicenter case-controlled study, the relationship between patterns of cannabis use and incidence of later psychosis was examined...
 Continue reading (Members only)
Risk of New-Onset Psychosis in ADHD is Higher with Amphetamine Than Methylphenidate
April 5, 2019   

Prescriptions for stimulants such as methylphenidate and amphetamine for the treatment of attention deficit -hyperactivity disorder (ADHD) have been on the rise. The Food and Drug Administration (FDA) mandated changes to drug labels for stimulants in 2007, on the basis of findings of...
 Continue reading
12345678
Top of Page